REFRACTORY LEUKEMIA
Clinical trials for REFRACTORY LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo tested in fight against Tough-to-Treat leukemias
Disease control Recruiting nowThis study is testing whether combining two new drugs, revumenib and mezigdomide, is a safe and effective treatment for people with specific types of acute leukemia that have come back or not responded to prior therapy. It will involve about 52 participants aged 12 and older who …
Matched conditions: REFRACTORY LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Radical Two-Part cell transplant trial offers hope for leukemia patients out of options
Disease control Recruiting nowThis early-phase study is testing a new two-step approach for patients with leukemia that has come back or not responded to standard treatments. First, patients receive chemotherapy and an infusion of immune cells from a partially matched donor to try to reduce the cancer. Then, …
Matched conditions: REFRACTORY LEUKEMIA
Phase: PHASE1 • Sponsor: Beijing 302 Hospital • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug cocktail tested for leukemia that Won't quit
Disease control Recruiting nowThis study is testing whether adding a drug called chidamide to a standard two-drug treatment is safe and more effective for adults whose acute myeloid leukemia has come back or hasn't responded to prior therapy. The goal is to see if this three-drug combination can help more pat…
Matched conditions: REFRACTORY LEUKEMIA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for Tough-to-Treat blood cancer: trial tests Triple-Drug attack
Disease control Recruiting nowThis study is testing whether adding a new oral drug, roginolisib, to two standard drugs (venetoclax and rituximab) is safe and works better for people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment. About 64 participants will receiv…
Matched conditions: REFRACTORY LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Jennifer R. Brown, MD, PhD • Aim: Disease control
Last updated Mar 02, 2026 15:27 UTC